Fundz

Zoetis to acquire VitalRADS for diagnostics boost

PUBLIC · ZTSJul 14, 2026

Acquiring Company

Zoetis

Acquired Company

VitalRADS

ParsippanyNew YorkBiotechnologyHealth CareMedicalAnimal FeedPetVeterinaryBiotechnologyHealth CareMedical DeviceHealth Diagnostics

Description

Zoetis has announced an agreement to acquire VitalRADS, a move aimed at enhancing its diagnostic services. This acquisition will enable Zoetis to accelerate the development of innovative diagnostic capabilities. The deal emphasizes Zoetis's commitment to improving animal health through advanced technology. Financial terms of the agreement have not been disclosed.

Who to call at Zoetis, and when

When Zoetis changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Zoetis raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Zoetis, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Zoetis. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Zoetis

Location

10 Sylvan Way

Parsippany, New Jersey, United States

About

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $7.8 billion in 2021 with approximately 12,100 employees. For more information, visit www.zoetis.com. DISCLOSURE NOTICES Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development, expected timing of product launches; the impact of the coronavirus (COVID-19) global pandemic and any recovery therefrom on our business, supply chain, customers and employees; future use of cash, dividend payments and share repurchases; tax rate and tax regimes and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. Such risks and uncertainties may be amplified by the COVID-19 global pandemic and its potential impact on the global economy and our business. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis. ZTS-COR ZTS-IR ZTS-FIN

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Zoetis makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Kristin
Senior decision-maker at this company
••••••••@••••••••

See Kristin's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Zoetis's next move

Learn about Strategic plan

Frequently asked

Who acquired VitalRADS?

VitalRADS was acquired by Zoetis, based in Parsippany. The deal was reported on July 14, 2026. As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. Zoetis is publicly traded (ZTS) and operates in Biotechnology.

When did Zoetis acquire VitalRADS?

Zoetis's acquisition of VitalRADS was reported on July 14, 2026. Zoetis has announced an agreement to acquire VitalRADS, a move aimed at enhancing its diagnostic services. This acquisition will enable Zoetis to accelerate the development of innovative diagnostic capabilities. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does VitalRADS do?

VitalRADS is an innovative company focusing on diagnostic imaging solutions and technologies. They specialize in providing advanced diagnostic services that enhance clinical decision-making. It is privately held, operating in Biotechnology, and is based in New York.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.